In vitro evaluation of the activity of an essential oil from Pistacia vera L. variety Bronte hull against Candida sp.
Antifungal
Candida sp.
Essential oil
Pistachio
Journal
BMC complementary and alternative medicine
ISSN: 1472-6882
Titre abrégé: BMC Complement Altern Med
Pays: England
ID NLM: 101088661
Informations de publication
Date de publication:
07 Jan 2019
07 Jan 2019
Historique:
received:
28
09
2018
accepted:
26
12
2018
entrez:
8
1
2019
pubmed:
8
1
2019
medline:
23
1
2019
Statut:
epublish
Résumé
Candida sp. represent the most common cause of fungal infections worldwide. In the present work, we have evaluated the activity of an essential oil extracted from pistachio hulls against a number of standard and clinical strains of Candida sp. C. albicans ATCC 64550, C. parapsilosis ATCC 22019, 4 clinical strains of C. albicans, 3 clinical strains of C. parapsilosis and 3 clinical strains of C. glabrata were used. All clinical isolates were identified by species-specific PCR-based methods. Susceptibility studies were performed using pistachio hull essential oil alone or in combination with antifungal compounds. The interactions between pistachio hull essential oil and selected antifungal compounds were also evaluated using the checkerboard method and the mechanisms of interaction investigated by droplet size distribution. Pistachio hull essential oil was fungicidal at the concentrations between 2.50 and 5.0 mg/ml. D-limonene and 3-Carene were the components with major activity. An antagonistic effect was observed with all combinations tested. The antifungal activity of pistachio hull essential oil could be used to help control resistance in Candida species. More studies need to be performed to elucidate the mechanisms responsible for the activity of pistachio hull essential oil.
Sections du résumé
BACKGROUND
BACKGROUND
Candida sp. represent the most common cause of fungal infections worldwide. In the present work, we have evaluated the activity of an essential oil extracted from pistachio hulls against a number of standard and clinical strains of Candida sp.
METHODS
METHODS
C. albicans ATCC 64550, C. parapsilosis ATCC 22019, 4 clinical strains of C. albicans, 3 clinical strains of C. parapsilosis and 3 clinical strains of C. glabrata were used. All clinical isolates were identified by species-specific PCR-based methods. Susceptibility studies were performed using pistachio hull essential oil alone or in combination with antifungal compounds. The interactions between pistachio hull essential oil and selected antifungal compounds were also evaluated using the checkerboard method and the mechanisms of interaction investigated by droplet size distribution.
RESULTS
RESULTS
Pistachio hull essential oil was fungicidal at the concentrations between 2.50 and 5.0 mg/ml. D-limonene and 3-Carene were the components with major activity. An antagonistic effect was observed with all combinations tested.
CONCLUSION
CONCLUSIONS
The antifungal activity of pistachio hull essential oil could be used to help control resistance in Candida species. More studies need to be performed to elucidate the mechanisms responsible for the activity of pistachio hull essential oil.
Identifiants
pubmed: 30612544
doi: 10.1186/s12906-018-2425-0
pii: 10.1186/s12906-018-2425-0
pmc: PMC6322278
doi:
Substances chimiques
Antifungal Agents
0
Oils, Volatile
0
Plant Oils
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Subventions
Organisme : Italian Ministry of Health
ID : GR-2011-02347606
Références
Diagn Microbiol Infect Dis. 2008 Oct;62(2):230-3
pubmed: 18640803
J Colloid Interface Sci. 2009 Feb 15;330(2):443-8
pubmed: 19038395
J Microbiol Methods. 2009 Oct;79(1):117-20
pubmed: 19635503
Nat Prod Commun. 2009 Jul;4(7):1007-10
pubmed: 19731613
Lett Appl Microbiol. 2010 Jul;51(1):83-9
pubmed: 20497495
Lett Appl Microbiol. 2011 Aug;53(2):193-7
pubmed: 21609344
J Nanobiotechnology. 2011 Sep 28;9:44
pubmed: 21952107
FEMS Microbiol Lett. 2013 Apr;341(1):62-7
pubmed: 23350629
Ther Clin Risk Manag. 2014 Feb 13;10:95-105
pubmed: 24611015
Med Mycol. 2015 Apr;53(3):275-84
pubmed: 25480017
PLoS One. 2015 Nov 18;10(11):e0142880
pubmed: 26580965
Food Chem. 2016 Apr 1;196:493-502
pubmed: 26593519
BMC Complement Altern Med. 2015 Nov 24;15:417
pubmed: 26601661
Evid Based Complement Alternat Med. 2015;2015:856243
pubmed: 26770255
Evid Based Complement Alternat Med. 2016;2016:3012462
pubmed: 28090211
Int J Mol Sci. 2017 Jun 06;18(6):null
pubmed: 28587291
Appl Microbiol Biotechnol. 2017 Sep;101(18):6993-7006
pubmed: 28766033
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28784671
Curr Opin Infect Dis. 2017 Dec;30(6):528-538
pubmed: 29095200
Molecules. 2018 Feb 13;23(2):null
pubmed: 29438274
Molecules. 2018 May 08;23(5):null
pubmed: 29738503
Food Chem. 2018 Sep 30;261:233-239
pubmed: 29739588
Antimicrob Agents Chemother. 1996 Aug;40(8):1914-8
pubmed: 8843303
J Clin Microbiol. 1998 Jun;36(6):1625-9
pubmed: 9620390
Antimicrob Agents Chemother. 1998 Aug;42(8):2002-5
pubmed: 9687397